Humacyte (HUMA) Return on Capital Employed (2021 - 2026)
Humacyte (HUMA) reported Return on Capital Employed of 117.08% for Q1 2026, down 3179.0% year-over-year from 3.8% in Q1 2025, and up 7.37% quarter-over-quarter from 126.4% in Q4 2025.
Humacyte (HUMA) Return on Capital Employed (2021 - 2026) Analysis & Trends
Humacyte (HUMA) has 6 years of Return on Capital Employed data on file, last reported at 117.08% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 117.08%, down 3179.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 117.08% (down 3179.0% YoY), and the FY2025 annual result was 99.44%, up 172.0% from the prior year.
- Return on Capital Employed advanced to 117.08% in Q1 2026 per HUMA's latest filing, from 126.4% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 31.43% in Q1 2022 and troughed at 126.4% in Q4 2025.
- A 5-year average of 77.1% and a median of 80.9% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2024: Return on Capital Employed soared 2255 bps in 2022, then plunged 4062 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 43.23% in 2022, then tumbled by 92 bps to 83.12% in 2023, then retreated by 29 bps to 107.56% in 2024, then decreased by 18 bps to 126.4% in 2025, then climbed by 7 bps to 117.08% in 2026.
- Business Quant data shows HUMA's Return on Capital Employed at 117.08% in Q1 2026, 126.4% in Q4 2025, and 117.69% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Humacyte | 183.21 Mn | 134.67 Mn | -1.54 Mn | -117.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -117.08% |
| Dec 31, 2025 | -126.40% |
| Sep 30, 2025 | -117.69% |
| Jun 30, 2025 | -85.86% |
| Mar 31, 2025 | -85.29% |
| Dec 31, 2024 | -107.56% |
| Sep 30, 2024 | -106.55% |
| Jun 30, 2024 | -80.90% |
| Mar 31, 2024 | -79.62% |
| Dec 31, 2023 | -83.12% |
| Sep 30, 2023 | -65.93% |
| Jun 30, 2023 | -56.99% |
| Mar 31, 2023 | -50.19% |
| Dec 31, 2022 | -43.23% |
| Sep 30, 2022 | -39.11% |
| Jun 30, 2022 | -33.75% |
| Mar 31, 2022 | -31.43% |
| Dec 31, 2021 | -28.60% |
| Sep 30, 2021 | -33.11% |
| Jun 30, 2021 | -56.29% |